Overview of the pharmacology of the aromatase inactivator exemestane (Q34788969)

4 August 2017

1 reference

title

Overview of the pharmacology of the aromatase inactivator exemestane (English)

1 reference

4 August 2017

1 reference

Robert W Brueggemeier

series ordinal

1

1 reference

4 August 2017

language of work or name

English

0 references

publication date

1 July 2002

1 reference

Breast Cancer Research and Treatment

4 August 2017

published in

1 reference

4 August 2017

volume

74

1 reference

4 August 2017

issue

2

1 reference

4 August 2017

page(s)

177-185

1 reference

Mechanisms of action of antiestrogens: relevance to clinical benefits and risks

4 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1016121822916

7 January 2021

Mechanism and inhibition of cytochrome P-450 aromatase

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1016121822916

7 January 2021

Biochemical and molecular aspects of aromatase

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1016121822916

7 January 2021

The Effect of an Aromatase Inhibitor, 4-Hydroxy-4-Androstene- 3,17-Dione, On Estrogen-Dependent Processes in Reproduction and Breast Cancer11

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1016121822916

7 January 2021

Modern techniques in radiological imaging related to oncology.

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1016121822916

7 January 2021

Theoretical considerations for the ideal aromatase inhibitor

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1016121822916

7 January 2021

Novel non-steroidal aromatase inhibitors: are there new perspectives in the treatment of breast cancer?

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1016121822916

7 January 2021

Effect of estrogen deprivation on the reproductive physiology of male and female primates

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1016121822916

7 January 2021

Novel aromatase and 5 alpha-reductase inhibitors

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1016121822916

7 January 2021

Aromatase inhibitors--mechanisms of steroidal inhibitors

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1016121822916

7 January 2021

Formestane. A review of its pharmacological properties and clinical efficacy in the treatment of postmenopausal breast cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1016121822916

7 January 2021

6-Methylenandrosta-1,4-diene-3,17-dione (FCE 24304): a new irreversible aromatase inhibitor

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1016121822916

7 January 2021

Pharmacological profiles of exemestane and formestane, steroidal aromatase inhibitors used for treatment of postmenopausal breast cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1016121822916

7 January 2021

Influence of anastrozole (Arimidex), a selective, non-steroidal aromatase inhibitor, on in vivo aromatisation and plasma oestrogen levels in postmenopausal women with breast cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1016121822916

7 January 2021

Novel irreversible aromatase inhibitors

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1016121822916

7 January 2021

Synthesis and aromatase inhibition by potential metabolites of exemestane (6-methylenandrosta-1,4-diene-3,17-dione)

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1016121822916

7 January 2021

Exemestane (FCE 24304), a new steroidal aromatase inhibitor

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1016121822916

7 January 2021

The minimal effective exemestane dose for endocrine activity in advanced breast cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1016121822916

7 January 2021

Aromatase inhibition for breast cancer treatment

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1016121822916

7 January 2021

Biology of aromatase inhibitors: pharmacology/endocrinology within the breast

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1016121822916

7 January 2021

Endocrinological and clinical evaluation of exemestane, a new steroidal aromatase inhibitor.

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1016121822916

7 January 2021

Second generation aromatase inhibitor--4-hydroxyandrostenedione

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1016121822916

7 January 2021

Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: results of a phase III randomized double-blind trial. The Exemestane Study Group.

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1016121822916

7 January 2021

Time-dependent inhibition of aromatase in trophoblastic tumor cells in tissue culture

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1016121822916

7 January 2021

Mechanisms of the actions of aromatase inhibitors 4-hydroxyandrostenedione, fadrozole, and aminoglutethimide on aromatase in JEG-3 cell culture

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1016121822916

7 January 2021

Aromatase inhibitors and enzyme stability

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1016121822916

7 January 2021

Breast tumor aromatase: functional role and transcriptional regulation

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1016121822916

7 January 2021

Comparison of in vitro exemestane activity versus other antiaromatase agents

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1016121822916

7 January 2021

Antiaromatase agents: preclinical data and neoadjuvant therapy.

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1016121822916

7 January 2021

Aromatization of androstenedione by cultured human fibroblasts

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1016121822916

7 January 2021

The interconversion and aromatization of androgens by human adipose tissue

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1016121822916

7 January 2021

Oestradiol synthesis from C19 steroids by human breast cancers

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1016121822916

7 January 2021

Multicenter, phase II trial of exemestane as third-line hormonal therapy of postmenopausal women with metastatic breast cancer. Aromasin Study Group

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1016121822916

7 January 2021

Third-line hormonal treatment with exemestane in postmenopausal patients with advanced breast cancer progressing on aminoglutethimide: a phase ii multicentre multinational study

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1016121822916

7 January 2021

Activity of exemestane in metastatic breast cancer after failure of nonsteroidal aromatase inhibitors: a phase II trial

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1016121822916

7 January 2021

Aromatase inhibitors in the treatment and prevention of breast cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1016121822916

7 January 2021

Arimidex (ZD1033): a selective, potent inhibitor of aromatase in postmenopausal female volunteers

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1016121822916

7 January 2021

Identifiers

DOI

10.1023/A:1016121822916

1 reference

Dimensions Publication ID

4 August 2017

1050005947

0 references

Fatcat ID

release_udiu6rkn5bar5kzuz5hes5fyvu

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/udiu6rkn5bar5kzuz5hes5fyvu

24 November 2022

mapped directly with Wikidata item

1 reference